Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product

Lysogene (LYS.PA) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered into a strategic manufacturing agreement with Brammer Bio, a best-in-class viral gene and cell therapy manufacturer.